Physician profile

David G Preskill

Obstetrics & Gynecology · Libertyville, IL

NPI 1386736338

$468.61

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$36.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Gynesonics, INC. $123.74 2021
Acessa Health INC. $80.30 2020
Allotrope Medical, INC $75.95 2021
Momentis Surgical INC. $47.00 2022
Hologic Sales and Service, LLC $45.04 2020-2022
Aspira Women'S Health INC $30.36 2021-2022
Astellas Pharma US INC $20.30 2023 Veozah
Myovant Sciences INC. $16.55 2022
Mayne Pharma Commercial LLC $16.04 2023
Olympus America INC. $13.33 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David G Preskill

$468.61

in general payments reported 2019-2025

Years
2020-2023
Top company
Gynesonics, INC.

https://glasscript.com/doctor/943598/david-g-preskill

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.